



   Objectives: 
While a moderate exercise produces beneficial effects on the cardiovascular system, consequences of a supraphysiological effort are not 
yet clear. The aim of our study was to evaluate the consequences of such an effort on cardiac markers, markers of inflammation but also 
markers of renal function. This project also studied the evolution of new biomarkers of cardiac fibrosis such as the ST2 and galectin-3. 
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 Materials and Methods: 
 
 51 people attending the Tor des Géants (330 km, with an altitude range of 24,000 meters) have been followed.  
The study is conducted on 33 participants having reached at least half of the race (148.7 km).  
Blood and urine samples were collected at four different times:  
•T1:halfway. 
•T0:before the race. 
•T2:at the finish . 
•T3:three days after arrival.  




  Results: 
During this ultra-endurance 
effort, the plasma levels of 
cardiac markers (hsTnT(Fig1), 
NT-proBNP (Fig3), copeptin 
(Fig4), H-FABP (Fig5), ST2 
(Fig6), Gal-3 (Fig7)), muscle (CK 
(Fig2), myoglobin) and 
inflammation (CRP DFO, GB) 
have increased significantly to 
halfway (148.7 km).  
Meanwhile, the markers of renal 
function (urinary NGAL and 
plasma and urinary creatinine) 
have only slightly varied, 
excepting plasma creatinine.  
 
Figure 1: hsTnT kinetic 
Figure 4: Copeptin kinetic 
Conclusions: The study suggests that there is no permanent structural damage at the myocardium level. However, the low pace adopted 
by the runners, due to fatigue, caused an inflammatory response as well as muscle damage less important than a shorter race. 
Nevertheless, an endurance race as the Tor des Géants means an intense physical and psychological effort. 
 
Figure 3: NT-ProBNP kinetic Figure  2: CKMB/CK ratio kinetic 
  
Impact of an ultra-trail of 330 km on plasma levels  
                    of cardiac biomarkers 
C.Le Goff1, JF Kaux2, L.Gergelé3, G.P.Millet4, M.Viallon3, P.Croisille3, E. Cavalier1 
 
1 Department of Clinical Chemistry, University Hospital of Liège, Liège, Belgium  
2 Department of motricity sciences, University Hospital of Liège, Liège, Belgium 
3 CHU de Saint Etienne, CREATIS, UMR CNRS 5220 INSERM U1040 INSA-Lyon, Université de Lyon, France 
4 Institute of Sports Sciences, University of Lausanne, Lausanne, Switzerland 
Figure 5: HFABP kinetic Figure 6: ST2 kinetic Figure 7: Gal 3 kinetic 
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